Bio-Rad Laboratories Inc
$ 277.00
0.00%
15 Apr - close price
- Market Cap 7,476,339,000 USD
- Current Price $ 277.00
- High / Low $ 277.00 / 277.00
- Stock P/E 9.95
- Book Value 276.16
- EPS 27.85
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.11 %
- 52 Week High 321.12
- 52 Week Low 234.41
About
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Analyst Target Price
N/A
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-13 | 2025-10-30 | 2025-08-01 | 2025-05-01 | 2025-02-13 | 2024-10-30 | 2024-08-01 | 2024-05-07 | 2024-02-29 | 2023-10-26 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 26.6548 | -12.6992 | 11.6718 | 2.2894 | -25.567 | 23.3401 | -76.2629 | 13.4533 | 3.1 | 2.33 | 3 | 3.34 |
| Estimated EPS | None | None | None | None | None | None | None | 2.99 | 2.84 | 2.76 | 2.64 | 3.63 |
| Surprise | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.4633 | 0.26 | -0.43 | 0.36 | -0.29 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | 349.9431% | 9.1549% | -15.5797% | 13.6364% | -7.989% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BIO-B
2026-04-01 14:40:45
The life science tools market is projected to reach $379.95 billion by 2030, growing at a CAGR of 13.5%. This growth is fueled by automation, increased investments in genomics and proteomics, demand for personalized medicine, and advancements in clinical diagnostics and drug discovery. Key players like F. Hoffmann-La Roche Ltd. and Thermo Fisher Scientific Inc. are driving innovation, exemplified by strategic acquisitions and the development of advanced sequencing platforms such as Illumina's MiSeq i100 series.
2026-03-26 20:38:51
The Vanguard Group filed an amended Schedule 13G/A for Bio-Rad Laboratories Inc. (NYSE: BIO), reporting beneficial ownership of 0 shares (0%) due to an internal realignment on January 12, 2026. This disaggregation of holdings means certain Vanguard subsidiaries will now report their holdings separately, in accordance with SEC guidelines. The filing, signed by Ashley Grim, Head of Global Fund Administration, indicates that Vanguard no longer has beneficial ownership over securities held by these re-aligned subsidiaries.
2026-03-17 07:10:14
Hound Partners LLC significantly reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 42.9% in the third quarter, now holding 103,963 shares valued at $29.15 million. This represents about 3.7% of Hound's portfolio. Despite mixed analyst sentiment with a "Hold" rating and a consensus target price of $358.50, Bio-Rad Laboratories reported an EPS of $2.51, missing the $2.57 consensus, and revenue of $693.2 million, almost 4% higher year-over-year.
2026-03-12 18:53:00
Natixis Advisors LLC significantly increased its stake in Bio-Rad Laboratories (NYSE:BIO) during Q3, purchasing an additional 26,119 shares, bringing their total to 65,069 shares valued at $18.25 million. This move is part of a broader trend of institutional investors modifying their positions in Bio-Rad, which currently has 65.24% of its stock owned by such entities. Despite missing recent EPS estimates by a narrow margin and trading with a P/E of 9.67, analysts maintain a "Hold" rating with an average target price of $358.50.
2026-03-12 13:09:26
Capital Research Global Investors has made a significant new investment in Bio-Rad Laboratories, purchasing 418,355 shares valued at approximately $117.3 million, representing about 1.55% ownership. This move comes as Bio-Rad reported Q4 EPS of $2.51, slightly missing estimates, with revenue up 3.9% year-over-year. The medical research company currently holds a "Hold" rating from analysts with a consensus price target of $358.50.
2026-03-12 10:52:26
Magnetar Financial LLC recently acquired 10,425 shares of Bio-Rad Laboratories (NYSE:BIO) valued at approximately $2.923 million, contributing to institutional investors owning about 65.24% of the stock. Bio-Rad Laboratories reported mixed financial results, missing EPS estimates slightly but showing a 3.9% increase in quarterly revenue year-over-year. Analysts currently hold a "Hold" consensus rating for the company with an average price target of $358.50.
